Media stories about BioScrip (NASDAQ:BIOS) have trended somewhat negative on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioScrip earned a news sentiment score of 0.00 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.4084076136508 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Financial Comparison: BioScrip (BIOS) versus The Competition (americanbankingnews.com)
- Comparing BioScrip (BIOS) & Its Peers (americanbankingnews.com)
- Head to Head Analysis: BioScrip (BIOS) and Its Peers (americanbankingnews.com)
- BioScrip (BIOS) vs. The Competition Financial Contrast (americanbankingnews.com)
- ETFs with exposure to BioScrip, Inc. : November 20, 2017 (finance.yahoo.com)
BioScrip (BIOS) opened at $2.51 on Wednesday. BioScrip has a fifty-two week low of $0.98 and a fifty-two week high of $3.39. The company has a debt-to-equity ratio of -6.11, a quick ratio of 1.60 and a current ratio of 1.91.
BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.02). The business had revenue of $198.70 million during the quarter, compared to the consensus estimate of $202.91 million. The company’s quarterly revenue was down 11.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.12) EPS. research analysts anticipate that BioScrip will post -0.63 EPS for the current fiscal year.
A number of analysts have recently weighed in on BIOS shares. ValuEngine raised BioScrip from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 9th. SunTrust Banks, Inc. reissued a “buy” rating and issued a $3.00 price objective on shares of BioScrip in a research report on Friday, November 3rd. BidaskClub cut BioScrip from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 1st. Zacks Investment Research cut BioScrip from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $4.00 price target (up previously from $3.00) on shares of BioScrip in a research report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. BioScrip currently has a consensus rating of “Hold” and a consensus price target of $3.60.
ILLEGAL ACTIVITY WARNING: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://ledgergazette.com/2017/11/22/somewhat-negative-press-coverage-somewhat-unlikely-to-impact-bioscrip-bios-stock-price.html.
In other BioScrip news, CEO Daniel E. Greenleaf acquired 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The shares were purchased at an average cost of $2.03 per share, for a total transaction of $30,450.00. Following the completion of the acquisition, the chief executive officer now owns 31,000 shares of the company’s stock, valued at approximately $62,930. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael G. Bronfein sold 27,000 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $2.69, for a total value of $72,630.00. Following the completion of the transaction, the director now owns 129,669 shares in the company, valued at $348,809.61. The disclosure for this sale can be found here. Insiders own 0.80% of the company’s stock.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.